Share Name Share Symbol Market Type Share ISIN Share Description
Avacta LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 73.50p 73.00p 74.00p 73.50p 73.50p 73.50p 66 07:55:35
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.2 -5.6 -6.9 - 50.27

Avacta Share Discussion Threads

Showing 3426 to 3449 of 3450 messages
Chat Pages: 138  137  136  135  134  133  132  131  130  129  128  127  Older
DateSubjectAuthorDiscuss
07/9/2017
15:44
I agree it sure looks like good news to me. Why are Avacta not making more of it?!
lantanatony
06/9/2017
15:56
It spells, or at least potentially, the end of the reproducibility crisis ... it is something quite astounding that seems lost on Mr Market. Imagine as a provider of diagnostics, or therapuetics (which is where it gets more interesting) being able to increase the incidence of your antibody, or antibody based compound, binding only the target proteins. Increase effective response while decrease the chance of unwanted bindings (potential side effects).
the drewster
06/9/2017
13:45
Drewster I agree this is all good stuff,but we need some better market traction. You would think a company from the sector would pay good money for such an assay?!
lantanatony
05/9/2017
11:12
Well worth a read: "A new paper (link is external) published recently in the Nature group journal, Scientific Reports, demonstrates the ability to combine the use of Affimers with antibodies to increase specificity and performance of a diagnostic tests against glypican-3, a cancer biomarker. The work was carried out by the Southern Medical University, Guangzhou in collaboration with the University of Leeds. The new assay offers a significant increase in specificity with results aligned to the ‘gold standard’ invasive immunohistochemical assay. The performance improvement observed with this new assay potentially provides a non-invasive test for monitoring cancer patients." Full article here: htTP://www.avacta.com/blogs/affimer-diagnostic-cancer-test-described-new-paper?utm_content=59838636&utm_medium=social&utm_source=twitter
the drewster
25/8/2017
15:40
Any one significant deal from any one of the many irons in the fire could be transformational, but an in-house cancer therapeutic with promising trials would send this into the multi-bagger territory. Not so long (in medical research terms) to wait. I'm happy with the various technical milestones that are being reached, and hope it's just a matter of time before the market wakes up to the technology and potential financial value.
the drewster
25/8/2017
07:45
Malcom Stacey has tipped on Share Prophets yesterday pointing to Alastair Smith's purchase. Not ure whether Shre Prophets counts as a credible tip!!
18bt
24/8/2017
23:41
Interesting and I agree it is very sad reading but I feel there are very different eyes on the company now. But as I have said before .... It's just a punt!
lantanatony
24/8/2017
16:45
Some history ... 2006 issue 4.5m shares at 225 on readmission - Mkt Cap £14.5m 2008 issued shares at prices above 500 to buy Oxford Medical Diagnostics ltd ... market cap then around £45m in March 2008 Subsequent cash raising activity: £2m @ 150 October 09 £1.95m @ 105 January '11 £4.7m @ 55 July '13 £10m @ 110 May '14 £22m @ 125 July '15 Weighted average, £40.65m @ 105 Update end July '17, that cash is c.£13m. Share price around 75p and Market Cap at about £52m
the drewster
21/8/2017
23:56
Bypooh I did very well out of Internet shares by following the big investors in and not so bad out of the Banks for the same reason. But if you know better, then so be it.
lantanatony
21/8/2017
23:56
Bypooh I did very well out of Internet shares by following the big investors in and not so bad out of the Banks for the same reason. But if you know better, then so be it.
lantanatony
21/8/2017
19:17
Perhaps that is the only way he can get another rights issue off the ground. Just my opinion.
poacher45
21/8/2017
14:40
CEO is positive, just bought 33k's worth.
tratante
21/8/2017
08:48
£1.25??? ... It was £1.40 wasn't it?
the drewster
20/8/2017
16:00
Institutional investors are not risking their own money, they play around with yours.
escapetohome
20/8/2017
14:19
lantanatony That is about as daft a comment as you can make. Practically all quoted companies have institutional investors. That does not seem to correlate with success. As for expertise, you must be joking. The same experts that created the internet bubble? Those that chased bank shares until they blew up? Those geniuses that stumped up £1.25 per share of Avacta two years ago?
bypooh
12/8/2017
22:20
Wan I am still waiting for your response to.why you think the institutional share holders are not picking up on your views. They have expert advice while you work in the property sector. Everyone can heve their say,but what makes you an expert?
lantanatony
12/8/2017
15:12
Wam I am grateful for your input its good to highlight other areas of interest which may have an affect on Avacta's goals. I recognise the risks but also the opportunity. Competition is the cornerstone of hunman achievement. We shall see soon what we have I guess within the next year.
danatkins
12/8/2017
09:26
Wan Why don't our large share holders share your views? After all they have expert advice!?
lantanatony
12/8/2017
08:09
Let's make this perfectly clear! The whole article is not available on III, it is only the full abstract. As on III the full abstract is also available in the link I provided with my comment and excerpt. The main thrust of my personal opinion, is that management have routinely overstated the development stages and the potential of Affimers. I further believe that any upfront payments are likely to remain tiny compared to what some are hoping for, in part due to the further development of Affimers that is necessary (and therefore not guaranteed) and indeed the wide choice of alternative scaffolds. Not to mention the improving antibody proposition and the reduction in costs of antibodies as eroding some of the advantages of Affimers. Recall that Abcam highlighted why, after extensively reviewing alternative scaffolds and technologies, they chose not to enter this market, but instead chose to further develop and improve antibodies - "After an extensive review of alternate scaffold and other in vitro technologies, we are confident that AxioMx has created unique, high quality and economically attractive methods to serve customers in research, diagnostic and drug discovery labs globally. We look forward to working with AxioMx to scale up their production and enhance our product offering." hxxp://www.abcam.com/index.html?pageconfig=news&rid=16668 Recall also that management routinely touted the fact that the time taken to generate high quality antibodies can be up to a year and was a major issue for many end users, compared to the process of finding an Affimer as taking around six weeks. That however has quietly been dropped, because in my view, it now takes considerably longer than originally stated (it gradually got longer in various statements). As mentioned in the article, the development of antibodies has not stood still, as indeed exemplified by Abcam's purchase of AxioMx - High Quality Antibodies. Developed Fast. In Just 8-10 Weeks. Unique to AxioMx is the speed at which we can develop a high affinity and specific, custom recombinant antibody. Central to this speed is the combination of our novel Rapid Liquid Screening and AxioMx Mutagenesis affinity maturation methodologies. hxxp://axiomxinc.com/services/custom-antibodies/
wan
12/8/2017
06:55
The whole artical Wan had showed can be viewed on III webite from poster Mol. It makes for an interesting read. One item I remember CEO stating at the last investors meeting which was recorded was they can extend the half-life I believe by joining up more than one protein so harder for the kidneys to flush out
danatkins
10/8/2017
15:15
Wan I don't think many Avacta share holders don't know that Avacta has potential competition. However,those most aware this will be the Avacta institutional investors. They will have done their homework and seem happy to hold on.
lantanatony
08/8/2017
12:37
I don't want to get drawn into conversation/debate here, but for an objective read (you can also buy/rent the whole article), the following perhaps puts some perspective on the non-antibody market, which is not a one-way street to fortune as there are in fact a lot of options/alternatives, and development of antibodies (and reduction in costs) are not standing still - July 2017 602 VOLUME 35 NUMBER 7 JULY 2017 NATURE BIOTECHNOLOGY Faster, deeper, smaller—the rise of antibody-like scaffolds Those are just two of the wide variety of pro-tein scaffold drugs currently in development (Tabl e 1 ). “There’s a whole zoo of non-anti-body scaffolds out there,” says Daniel Christ, an immunologist at the Garvan Institute of Medical Research in Sydney, Australia. Third, scaffolds are sufficiently different from antibodies that they can be patented. In the mid-1990s when research into scaffolds began in earnest most antibody drugs were still patent-protected. An alternative drug candidate could claim novelty and be considered a patentable invention for the same therapeutic action. These intellectual property and cost advan-tages are beginning to erode, however. “The antibody field is not standing still, it has been improving over the years,” says Christ. Patents, including for those protecting antibody block-busters Herceptin (trastuzumab), Humira (adalimumab) and Avastin (bevacizumab), are beginning to expire before the alternative scaffolds make it to market, and new manufac-turing techniques are driving down the cost of biologics drug production anyway. Even scaf-folds’ small size is not always desirable. “Small size is a double-edged sword,” says Christ. “It means they also have a short half-life.” Full Nature article available here - hxxp://www.readcube.com/articles/10.1038/nbt0717-602?r3_referer=nature
wan
08/8/2017
12:00
Poacher45 What you say is true. However there are very different eyes on the company now. But a hostile bid could spoil the party. It is still a punt but could be worthwhile. At the current share price it is small beer for most In the Bio Phama sector.
lantanatony
08/8/2017
11:56
Still 50/50 here and I'm invested. My views is business for Avacta has/is coming to a tipping point. Although we will need more cash soon that is I think a given but the share could be trading higher when that time comes. Of course that will be driven by future deals. We have assets ie the animal health side which could be sold and I'm sure this has been tabled as an idea but its too early to sell IMO. We have institutions backing this so I'm sure they will be happy to pony up more cash if the future looks good. Just hope PIs will also get the opportunity. In hind sight I should have sold and invested in IQE at 16P. At that time the BBs were negative on the company. Maybe that's when to buy when everyone is being negative about a company
danatkins
Chat Pages: 138  137  136  135  134  133  132  131  130  129  128  127  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20170921 08:53:20